After UCB’s psoriasis drug bimekizumab hit an FDA wall in May thanks to issues with facility inspections, the drug is back on the FDA’s waiting list. The agency accepted UCB’s biologics license application resubmission and designated it as Class 2, complete with a six-month review period.
With this development, the FDA’s decision on the application is expected by the second quarter of 2023. UCB sent in the resubmission in November after receiving an FDA complete response letter in May. At the time, the agency couldn’t consider the approval because “certain pre-approval inspection observations” were outstanding at the time.
That setback came after a delay for the company in October 2021 because the FDA couldn’t inspect European facilities due to COVID-related travel restrictions.
UCB’s drug is a humanized monoclonal IgG1 antibody that selectively inhibits interleukin 17A (IL-17A) and interleukin 17F, which are two key cytokines that drive inflammatory processes. It’s already gained approvals in Europe and Great Britain plus Japan, Canada, Australia, Saudi Arabia and Switzerland.
Thanks to the six-month review period, the first half of 2023 should be quiet for UCB, while the second will likely show growth thanks to strong U.S. sales, ODDO BHF analysts wrote in a note to clients. The company could have three approvals next year in bimekizumab plus the rare disease duo of zilucoplan and rozanolixizumab. Before these approvals, which should start with bimekizumab, ODDO BHF analysts anticipate “another five tough months.”
Back in June, the company already had to reduce its profit forecast for 2022 thanks to generic competition, inflation and the complete response letter.
Meanwhile, earlier this month, UCB touted results from two phase 3 trials of bimekizumab in hidradenitis suppurativa. In the inflammatory skin disease, the drug showed improvement over placebo in reducing patient’s skin abscesses and inflammatory nodules. UCB plans to start global filings for that indication during the third quarter of 2023.
By Zoey Becker
Source: fiercepharma.com
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
